We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PDAC

News List

Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021 prnasia
June 07, 2021
Alphamab Oncology announced that data from a Phase II study (KN046-IST-04) of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for pancreatic ductal adenocarcinoma (PDAC) was presented in a poster session at the ASCO 2021.
Triple combination of therapies shows promise in pancreatic cancer trial europeanpharmaceuticalreview
December 18, 2020
The combination of motixafortide, KEYTRUDA® and chemotherapy met all trial endpoints, including increasing overall and progression free survival.
BioLineRx Announces Initiation of Triple Combination Arm of Pancreatic Cancer Study americanpharmaceuticalreview
December 12, 2018
BioLineRx announced the initiation of the triple combination arm of the Phase 2a COMBAT/KEYNOTE-202 study in patients with metastatic pancreatic cancer (PDAC) under its immuno-oncology.....